Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incedence and Prevalence of Influenza
4.2.2 Increasing R&D Initiatives in Development of Novel and Advanced Drugs for the Treatment of Influenza
4.3 Market Restraints
4.3.1 High cost of Drug Development
4.3.2 Side effects Asoociated with Antiviral Therapy
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Antiviral Drugs
5.1.2 Antihistamines
5.1.3 Vaccines
5.1.4 Other
5.2 By Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Independent Pharmacy and Drug Store
5.2.3 Online Pharmacy
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biondvax
6.1.2 Daiichi Sankyo Company
6.1.3 F. Hoffmann-La Roche Ltd.(Genentech USA, Inc.)
6.1.4 GlaxoSmithKline
6.1.5 Genentech USA, Inc.
6.1.6 NATCO Pharma Limited
6.1.7 Novartis AG
6.1.8 Sanofi
6.1.9 Seqirus


7 MARKET OPPORTUNITIES AND FUTURE TRENDS